Origin Agritech Ltd. (NASDAQ: SEED) (the “Company” or “Origin”), an agriculture technology company, today announced that the Company has entered into a collaboration agreement with Biotechnology Research Institute (BRI), a division of Chinese Academy of Agriculture Sciences (CAAS) to expand collaborations in GMO soybean research and commercialization.
In addition to glyphosate tolerance G2-epsps gene, which BRI developed and Origin has global exclusive commercial rights in corn, soybean, and other major crops, Origin and BRI will expand our collaboration to develop dicamba tolerance, drought tolerance, and salt-alkaline tolerance GMO soybean varieties by using three BRI newly developed and patented genes.
Over the years, Origin has been cooperating with BRI in developing various GM traits, including GMO phytase corn, glyphosate tolerance corn, and double stacked insect resistance and glyphosate tolerance corn. The phytase corn trait received bio-safety approval in 2009.
A number of elite phytase commercial corn hybrids have been developed and pending for variety bio-safety approval. Glyphosate tolerance corn and double stacked insect resistance/glyphosate tolerance corn have completed most trails and are in the government approval process. By using G2-epsps gene, BRI developed GMO glyphosate tolerance soybean, which received a bio-safety certificate on July 15, 2020.
The new collaboration agreement deepens Origin’s cooperation with BRI and mainly focuses on related research and commercialization of GMO soybean. BRI will focus on fundamental research and provide technical support to Origin on GMO soybean product development and global commercialization.
“We are very pleased to further deepen our collaboration with Origin,” said Dr. Li Xinhai, director of BRI, “the new agreement will definitely promote GMO soybean research and commercialization which will increase soybean production and benefit Chinese farmers and consumers in China as well as other parts of the world.”